Part 6/10:
The pioneering research demonstrates that this dried blood spot test, which requires as little as 0.05 mL of blood, not only presents greater accuracy than traditional tests but also exhibits stability in transport and analysis. Unlike former biomarkers that faltered during drying processes, metabolites retain their integrity, allowing for both cost-effectiveness and greater accessibility.
This innovative fusion of dried blood analysis and AI technology offers a beacon of hope—particularly for underserved communities that often lack the resources for expensive diagnostic tools. Currently, only a small fraction of global cancer spending reaches regions heavily impacted by cancer, making this method a vital advancement.